MarketCap
Facebook
X
TelegramAnnual report 2023
added 03-06-2024
Endo International plc Total Assets 2011-2026 | ENDP
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Endo International plc
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.14 B | 5.76 B | 8.77 B | 9.26 B | 9.39 B | 10.1 B | 11.6 B | 14.3 B | 19.4 B | 10.9 B | 6.57 B | 6.57 B | 7.29 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19.4 B | 5.14 B | 9.62 B |
Quarterly Total Assets Endo International plc
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.26 B | 5.42 B | 5.57 B | 5.76 B | 6.01 B | 6.36 B | 8.45 B | 8.77 B | 9.25 B | 9.21 B | 9.23 B | 9.26 B | 9.26 B | 9.26 B | 9.26 B | 9.39 B | 9.39 B | 9.39 B | 9.39 B | 10.1 B | 10.1 B | 10.1 B | 10.1 B | 11.6 B | 11.6 B | 11.6 B | 11.6 B | 14.3 B | 14.3 B | 14.3 B | 14.3 B | 19.4 B | 19.4 B | 19.4 B | 19.4 B | 10.8 B | 10.9 B | 10.9 B | 10.9 B | 6.57 B | 6.57 B | 6.57 B | 6.57 B | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 19.4 B | 5.26 B | 10.4 B |
Total Assets of other stocks in the Drug manufacturers industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
29.7 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
154 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
431 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
10.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
10.9 M | - | 0.86 % | $ 117 M | USA |
 |
China Pharma Holdings
CPHI
|
14.9 M | $ 0.57 | -9.62 % | $ 9.95 M |  China |
 |
Eagle Pharmaceuticals
EGRX
|
406 M | - | -39.89 % | $ 27.7 M | USA |
 |
Aurora Cannabis
ACB
|
853 M | $ 3.32 | 0.3 % | $ 86.3 M |  Canada |
 |
Catalent
CTLT
|
9.75 B | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
204 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
164 M | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
1.93 B | $ 2.58 | 2.38 % | $ 1.34 B | Canada |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
1.82 B | $ 8.01 | -0.5 % | $ 410 M | USA |
 |
Evoke Pharma
EVOK
|
7.07 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
681 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
75.6 M | $ 3.13 | 2.62 % | $ 44 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
289 M | - | - | $ 193 M | Canada |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 4.99 | -2.25 % | $ 1.82 B | Canada |
 |
Pacira BioSciences
PCRX
|
1.55 B | $ 23.2 | 2.43 % | $ 1.07 B | USA |
 |
Harrow Health
HROW
|
399 M | $ 35.2 | 3.53 % | $ 1.29 B | USA |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
108 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
76.6 M | - | -27.8 % | $ 2.56 M | USA |
 |
Perrigo Company plc
PRGO
|
8.54 B | $ 9.64 | 0.73 % | $ 1.34 B | USA |
 |
ProPhase Labs
PRPH
|
87.6 M | - | - | $ 5.07 M | USA |
 |
Evolus
EOLS
|
226 M | $ 4.43 | -5.34 % | $ 286 M | USA |
 |
Radius Health
RDUS
|
182 M | - | - | $ 1.42 B | USA |
 |
Sundial Growers
SNDL
|
1.34 B | $ 1.37 | 0.74 % | $ 3.37 M | Canada |
 |
Rockwell Medical
RMTI
|
52.2 M | $ 1.03 | 0.98 % | $ 24 M | USA |
 |
Relmada Therapeutics
RLMD
|
94 M | $ 6.1 | 4.1 % | $ 241 M | USA |
 |
OrganiGram Holdings
OGI
|
408 M | $ 1.34 | -1.47 % | $ 402 M | Canada |
 |
SCYNEXIS
SCYX
|
59 M | $ 0.9 | 2.8 % | $ 44.9 M | USA |
 |
Jupiter Wellness
JUPW
|
7.34 M | - | - | $ 33.6 M | USA |
 |
Solid Biosciences
SLDB
|
233 M | $ 6.68 | -6.44 % | $ 585 M | USA |
 |
Lannett Company
LCI
|
484 M | - | 1.15 % | $ 7.11 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
13.7 M | $ 2.34 | -8.24 % | $ 2.9 M | USA |
 |
Organogenesis Holdings
ORGO
|
498 M | $ 2.41 | -2.43 % | $ 317 M | USA |
 |
Canopy Growth Corporation
CGC
|
918 M | $ 0.96 | -0.87 % | $ 103 M | Canada |
 |
Tilray
TLRY
|
4.31 B | $ 6.66 | 3.26 % | $ 4.12 B | Canada |
 |
Assertio Holdings
ASRT
|
267 M | $ 16.51 | 17.93 % | $ 106 M | USA |
 |
TherapeuticsMD
TXMD
|
43.3 M | $ 2.29 | -0.87 % | $ 23.9 M | USA |
 |
Recro Pharma
REPH
|
153 M | - | -4.76 % | $ 65.3 M | USA |
 |
Veru
VERU
|
60.4 M | $ 2.29 | -0.43 % | $ 309 M | USA |
 |
Viatris
VTRS
|
50 B | $ 13.36 | 0.53 % | $ 16 B | USA |
 |
cbdMD
YCBD
|
10.6 M | $ 0.77 | 1.06 % | $ 3.32 M | USA |
 |
Tricida
TCDA
|
169 M | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
55.5 M | - | - | $ 55.5 M | USA |